Interferon-alpha-induced depression: Comparisons between early- and late-onset subgroups and with patients with major depressive disorder
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Interferon (IFN)-alpha, until recently the standard treatment of hepatitis C virus (HCV) infection, is associated with a significant risk of major depressive episode (MDE, or IFN-alpha-induced depression). However, it is little studied the comparisons of clinical manifestations between IFN-alpha-induced depression and major depressive disorder (MDD). In addition, IFN-alpha induces different neuroinflammation and neuroendocrine status throughput the HCV treatment course; however, the clinical presentations have never been compared between early-onset and later-onset IFN-alpha-induced depression. We assessed 200 HCV patients starting IFN-alpha therapy bi-weekly for 24 weeks, with the structured interview for confirmation of diagnosis of IFN-alpha-induced depression and with clinical rating scales for depressive symptoms and neuropsychiatric symptoms. Subjects developed IFN-alpha-induced depression (n = 59, 30%) during the first 6 weeks of IFN-alpha therapy were defined as the early-onset group (n = 32), while those developed depression after the 6th week were defined as the late-onset group (n = 27). A matched group of MDD patients (n = 60) was used to compare specific clusters of depressive symptoms with early- and late-onset IFN-alpha-induced depression. Compared to the matched group of MDD patients, IFN-alpha-induced depression was significantly associated with more somatic symptoms and fewer symptoms of mood, anxiety and negative cognition. More somatic symptoms were also found in those who became clinically depressed at early stage of IFN-alpha therapy. We suggest that the specific somatic features of interferon-alpha-induced depression, and especially of early-onset depression, characterise individuals who are more sensitive to cytokines-induced changes in mood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Development of a fatigue scale
Chalder, T., Berelowitz, G., Pawlikowska, T., Watts, L., Wessely, S., Wright, D., & Wallace, E. P. (1993) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(93)90081-p · Cited by 3,032 · cited 4×
“Professor Pariante was additionally supported by the Medical Research Council grant Persistent Fatigue Induced by Interferon-alpha: A New Immunological Model for Chronic Fatigue Syndrome (MR/J002739/1) and by the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundat…”
BackgroundMethodInfluentialCytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · cited 1×
“is responsive to standard antidepressant therapy (Capuron et al., 2002a; Farah, 2002; Musselman et al., 2001); (ii) is associated with alterations in monoamine metabolism and its metabolic enzyme, indoleamine 2,3, dioxygenase (IDO) (Capuron et al.”
BackgroundCapuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797 · cited 7×
“…indeed induces major depression is that IFN-alpha-induced depression (Raison et al., 2006): (i) is responsive to standard antidepressant therapy (Capuron et al., 2002a; Farah, 2002; Musselman et al., 2001); (ii) is associated with alterations in monoamine metabolism and its metabolic enzyme,…”
BackgroundInfluentialRaison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 3×
“…al., 2005b); (iii) is associated with alterations in hypothalamic-pituitaryadrenal (HPA) axis function (Capuron et al., 2003b; Raison et al., 2010a; Raison et al., 2010c); and (iv) can be effectively prevented by antidepressant agents, including specific serotonin reuptake inhibitors (Jiang et…”
BackgroundCytokines and psychopathology: Lessons from interferon-α
Capuron, L., & Miller, A. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.009 · Cited by 562 · cited 1×
“…all patients experience an acute sickness behaviour with flu-like symptoms and neuropsychiatric adverse effects induced by IFN-alpha (inflammation) (Capuron and Miller, 2004; Dieperink et al., 2000; Raison et al., 2005; Trask et al., 2000), which resemble the effects of cytokine administration in…”
BackgroundInterferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Capuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., & Dantzer, R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000995 · Cited by 473
Cited by
Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis
Wu, A., & Zhang, J. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02964-x · Cited by 306
Depression, dementia and immune dysregulation
Hayley, S., Hakim, A. M., & Albert, P. R. (2021) · Brain · doi:10.1093/brain/awaa405 · Cited by 186
Cordaro, M., Cuzzocrea, S., & Crupi, R. (2020) · Antioxidants · doi:10.3390/antiox9030216 · Cited by 98
Zhang, K., Liu, R., Gao, Y., Ma, W., & Shen, W. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s274778 · Cited by 39
Neuroimmune Advance in Depressive Disorder
Zhao, G., & Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9271-0_4 · Cited by 20
Mandal, G., Kirkpatrick, M., Alboni, S., Mariani, N., Pariante, C. M., & Borsini, A. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae041 · Cited by 15
“Both animal models and clinical studies demonstrate an increased inflammatory milieu associated with depression, including increased levels of interleukin-1beta (IL-1b), IL-6, tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFN-g) (Su et al., 2019; Osimo et al., 2020; Das et al., 2021).”
Self-citation
Metadata
- Authors
- Su, K.-P., Lai, H.-C., Peng, C.-Y., Su, W.-P., Chang, J. P.-C., & Pariante, C. M.
- Venue
- Brain, Behavior, and Immunity
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 80
- Pages
- 512-518
- ISSN
- 0889-1591 (ISSN-L)
- OpenAlex
- W2943544933
- Cited by
- 68
- References
- 24
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.